Evidence map›Paper›PMID 27875276›Full record

ArticleJournal of cell science2016

Cancer cells become less deformable and more invasive with activation of β-adrenergic signaling.

Tae-Hyung Kim, Navjot Kaur Gill, Kendra D Nyberg, Angelyn V Nguyen, Sophia V Hohlbauch, Nicholas A Geisse, Cameron J Nowell, Erica K Sloan, Amy C Rowat

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cell science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Beta-blocker use and breast cancer outcomes: a meta-analysis.Breast cancer research and treatment · 2024
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Focus on mechano-immunology: new direction in cancer treatment.International journal of surgery (London, England) · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. βCells · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Tae-Hyung KimDepartment of Integrative Biology and Physiology, University of California, Los Angeles 90095, USA.ORCID 0000-0002-5045-4401
Navjot Kaur GillDepartment of Integrative Biology and Physiology, University of California, Los Angeles 90095, USA.
Kendra D NybergDepartment of Integrative Biology and Physiology, University of California, Los Angeles 90095, USA.
Angelyn V NguyenDepartment of Integrative Biology and Physiology, University of California, Los Angeles 90095, USA.
Sophia V HohlbauchAsylum Research, an Oxford Instruments Company, Santa Barbara, CA 93117, USA.
Nicholas A GeisseAsylum Research, an Oxford Instruments Company, Santa Barbara, CA 93117, USA.
Cameron J NowellDrug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Erica K SloanSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles 90095, USA.
Amy C RowatDepartment of Integrative Biology and Physiology, University of California, Los Angeles 90095, USA rowat@ucla.edu.ORCID 0000-0001-5800-5320
University of California, Los Angeles · USOxford Instruments (United States) · USMonash University · AU

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
Adrenergic regulation of tumor inflammation and metastatic disseminationR01CA160890 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SLOAN, ERICA KATE · 2012 to 2016
$1.6M
NCATS NIH HHS UL1 TR000124NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA160890NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

Invasion by cancer cells is a crucial step in metastasis. An oversimplified view in the literature is that cancer cells become more deformable as they become more invasive. β-adrenergic receptor (βAR) signaling drives invasion and metastasis, but the effects on cell deformability are not known. Here, we show that activation of β-adrenergic signaling by βAR agonists reduces the deformability of highly metastatic human breast cancer cells, and that these stiffer cells are more invasive in vitro We find that βAR activation also reduces the deformability of ovarian, prostate, melanoma and leukemia cells. Mechanistically, we show that βAR-mediated cell stiffening depends on the actin cytoskeleton and myosin II activity. These changes in cell deformability can be prevented by pharmacological β-blockade or genetic knockout of the β

Indexed as

Signal TransductionActinsCalciumCell Line, TumorCell MovementHumansIsoproterenolModels, BiologicalNeoplasm InvasivenessNeoplasmsReceptors, Adrenergic, beta-2ActinsCalciumIsoproterenolReceptors, Adrenergic, beta-2Atomic force microscopyCancerCell mechanical propertiesInvasionMechanotypeParallel microfiltrationβ2-adrenergic receptor

Identifiers

PMID27875276
PMCPMC5201020
OpenAlexW2556595436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.